Please login to the form below

Not currently logged in
Email:
Password:

Aspen

This page shows the latest Aspen news and features for those working in and with pharma, biotech and healthcare.

Grünenthal buys Zomig rights as AZ slimming drive continues

Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

Latest news

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... The five generic medicines - chlorambucil,

  • Italian pharma scandals prompts call for EU-wide pricing probe Italian pharma scandals prompts call for EU-wide pricing probe

    Aspen fined 5.2m for threat to halt supply of cancer drugs if price hikes not accepted. ... The negotiation strategy adopted by Aspen was so aggressive as to reach the credible threat of interrupting the direct supply of the drugs to the Italian market,"

  • AstraZeneca sells rights to seven anaesthetics in $770m deal AstraZeneca sells rights to seven anaesthetics in $770m deal

    Ten-year agreement with Aspen continues the streamlining of its operations. AstraZeneca has divested seven drugs from its anaesthetics portfolio through a $770m deal with Aspen Global Incorporated (AGI). ... The deal is due to be completed in the third

  • Endo buys Par for $8bn as M&A mania marches on Endo buys Par for $8bn as M&A mania marches on

    All told Endo has already spent around $10bn on M&A in recent months, closing a generics deal with South Africa's Aspen Holdings earlier this month.

  • GSK sells another chunk of South Africa's Aspen GSK sells another chunk of South Africa's Aspen

    In the same year, Aspen also took control of a GSK generic drugs unit in Australia and bought one of the UK-based company's manufacturing facilities in France. ... We continue to believe in the strategy of Aspen and we remain committed to working

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    $330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014.

  • Deal Watch September 2016 Deal Watch September 2016

    Reflecting a long standing business relationship, Aspen paid GSK £180m to acquire Ultiva, Nimbex, Tracrium, Mivacron and Anectinein, plus up to £100m in milestone payments. ... 500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva,

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

  • Pharma deals in May 2015 Pharma deals in May 2015

    360. Aspen/ Strides Arcolab. Divestment. Range of branded and generic drugs.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence, option and collaboration. 164. Novartis/Aspen. Purchase of the heparin based anticoagulant Mono-Embolex, with sales of 68m in 2013.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,

  • Compliance Hub Ltd

    Address:. Aspen Farm. Sheep Lane Woburn. Bedfordshire. MK17 9HD. UK.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics